Meconium has also been identified as a risk factor for microbial invasion of the amniotic cavity. 7, 8 In vitro, it has been found to enhance bacterial growth 9,1 and impair immune function. 11 Clinically, meconium is associated with an increased incidence of chorioamnionitis 11-a4 and endometritis.3, 4 One study has shown a significant reduction in 
econium aspiration syndrome, an uncommon but serious neonatal complication, occurs most often in term or postterm infants who pass meconium in utero. Meconium-stained amniotic fluid (MSAF) complicates 8-16% of all deliveries. Though controversial in the absence of variable decelerations, z amnioinfusion is standard treatment for patients with MSAF at our institution and others. By diluting meconium, amnioinfusion has been associated with decreased frequency of thick meconium, 3, 4 less meconium below the neonate's vocal cords, 3 -s and a decrease in the rate of meconium aspiration syndrome. 3, 6, 8 Meconium has also been identified as a risk factor for microbial invasion of the amniotic cavity. 7, 8 In vitro, it has been found to enhance bacterial growth 9,1 and impair immune function. 11 Clinically, meconium is associated with an increased incidence of chorioamnionitis 11-a4 and endometritis. 3, 4 One study has shown a significant reduction in 
RESULTS
Over the 18-month study period, 200 patients were enrolled and randomized, 100 each to the cefazolin and placebo groups. Seventeen patients were excluded from data analysis. Three of these patients delivered before amnioinfusion could be administered, two received intravenous antibiotics for sub- Because many patients certainly delivered before receiving the entire liter of amnioinfusion and some of the antibiotic remains in suspension and flows back out of the cervix, the dose of cefazolin delivered was likely less than one gram, and a larger amount of cefazolin in the suspension may have been more efficacious.
As stated previously, intravenous ampicillinsulbactam given prophylactically in this setting has been shown to significantly reduce the rate of clinical chorioamnionitis. 15 However, utilization of more narrow spectrum agents for prophylaxis seems prudent, since broad-spectrum agents used in this manner may select for resistant and more virulent strains of microorganisms.
Cefazolin added prophylactically to amnioinfusions administered for MSAF did not significantly reduce the rates of maternal or neonatal infection in this study. Further investigation is needed to elucidate the appropriate role, if any, for antibiotic prophylaxis in patients with this condition.
